<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preoperative evaluation and perioperative management of patients with rheumatic diseases</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preoperative evaluation and perioperative management of patients with rheumatic diseases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preoperative evaluation and perioperative management of patients with rheumatic diseases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Axford, DSc, MD, FRCP, FRCPCH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert H Shmerling, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephanie B Jones, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marianna Crowley, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Clinicians caring for patients with rheumatic diseases must be aware that there are specific issues involved in their pre- and postoperative management [<a href="#rid1">1,2</a>].</p><p>Areas of special concern for patients with rheumatic diseases who are having surgery will be discussed here. General issues in preoperative medical consultation and perioperative management are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient"</a> and  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a> and  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PREOPERATIVE EVALUATION</span></p><p class="headingAnchor" id="H3"><span class="h2">History and physical examination</span><span class="headingEndMark"> — </span>All patients require a careful preoperative history and physical examination, with further evaluation indicated in some individuals. Some particular concerns among patients with rheumatic diseases include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Several rheumatic diseases are associated with increased risks of coronary artery disease, arrhythmias, heart failure, or cardiac death. (See  <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">"Coronary artery disease in systemic lupus erythematosus"</a>.)</p><p></p><p class="bulletIndent1">Determining cardiovascular risk may be more difficult because many patients with rheumatic diseases are not physically active, making assessment of functional status and cardiac symptoms unreliable. An exercise or pharmacologic stress test may be necessary in some circumstances to adequately assess the risk of perioperative myocardial infarction. (See  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway management for anesthesia may be difficult in patients with cervical spine or temporomandibular joint disease. Airway manipulation in patients with severe cervical subluxation can result in spinal cord injury or death. (See  <a class="medical medical_review" href="/z/d/html/7518.html" rel="external">"Cervical subluxation in rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/90615.html" rel="external">"Management of the difficult airway for general anesthesia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited range of motion of other joints or joint pain may make positioning for surgery complicated. As an example, patients with shoulder pain may have difficulty lying in the lateral decubitus position for hip surgery.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Preoperative laboratory testing should be based on patient-specific factors and the planned surgical procedure. (See  <a class="medical medical_review" href="/z/d/html/4816.html" rel="external">"Preoperative medical evaluation of the healthy adult patient", section on 'Laboratory studies'</a> and  <a class="medical medical_review" href="/z/d/html/94539.html" rel="external">"Preoperative evaluation for anesthesia for noncardiac surgery", section on 'Clinical evaluation'</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">GENERAL MANAGEMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Perioperative care in patients with rheumatic diseases requires special attention to the following issues:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessing disease activity and optimizing the medication regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Recognizing the increased cardiovascular risk associated with rheumatic diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Reducing thrombosis risk in patients with antiphospholipid syndrome (APS)</p><p class="bulletIndent1"><span class="glyph">●</span>Minimizing risk of surgical site infections in the setting of immunosuppressive medications</p><p></p><p class="headingAnchor" id="H2961524864"><span class="h2">Assessment of disease activity</span><span class="headingEndMark"> — </span>Prior to elective surgery, patients should be evaluated by their rheumatologist to assess disease activity and identify major organ involvement that may impact the surgery. Ideally, patients should undergo surgery during periods when their disease is well controlled and they are on an optimized medication regimen. Appropriate testing will vary by disease. (See <a class="local">'Disease-specific issues'</a> below.)</p><p class="headingAnchor" id="H2804869241"><span class="h2">Cardiac risk assessment</span><span class="headingEndMark"> — </span>When performing a preoperative cardiac risk assessment, providers should consider the increased risk of cardiovascular disease among patients with inflammatory diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). (See  <a class="medical medical_review" href="/z/d/html/7492.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Implications for prevention and management", section on 'Risk estimation'</a> and  <a class="medical medical_review" href="/z/d/html/4683.html" rel="external">"Coronary artery disease in systemic lupus erythematosus", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/6616.html" rel="external">"Evaluation of cardiac risk prior to noncardiac surgery"</a>.)</p><p class="headingAnchor" id="H3128258517"><span class="h2">Management of thrombophilia in antiphospholipid syndrome</span><span class="headingEndMark"> — </span>Patients with APS may be at increased risk of thrombosis. Management of such patients depends upon their specific drug regimen and whether or not they have APS. The treatment of APS and the management of patients receiving anticoagulants in the perioperative setting are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a> and  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Primary thrombosis prevention'</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Medication management</span><span class="headingEndMark"> — </span>The optimal strategy for managing immunosuppressive therapies during the perioperative period is unknown due to the lack of evidence. We discuss our approach to management of the major categories of medications used for the treatment of various rheumatic diseases in the perioperative setting below; it is largely based on low-quality evidence and expert opinion. A rheumatologist should be involved in the medication management around the time of surgery.</p><p>Our approach is generally consistent with the guidelines proposed by the American College of Rheumatology and the American Association of Hip and Knee Surgeons for the perioperative management of various immunosuppressive medications in patients undergoing total hip and knee arthroplasty [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H6802267"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>The major concerns with regard to glucocorticoid use in the setting of surgery are the risk of surgical site infections and the risk of hemodynamic instability (secondary to glucocorticoid-induced adrenal insufficiency). Ideally, the lowest possible dose of glucocorticoids should be used in the perioperative setting in order to minimize these risks. If patients require greater than 10 mg <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent) daily, it would imply that the disease activity is not adequately controlled and that elective surgery should be postponed. Therefore, we suggest that the dose of prednisone is less than or equal to 10 mg per day before surgery is planned. Patients should continue their outpatient glucocorticoid dose perioperatively, which may require parenteral administration (of the equivalent dose) if a patient is taking nothing by mouth.</p><p>Limited data suggest that the risk of infection associated with glucocorticoids is lower when the daily dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> does not exceed 10 to 15 mg. A propensity score-matched study using insurance claims data from 9911 adults with RA undergoing elective total knee or hip arthroplasty found that glucocorticoid use was associated with a dose-dependent increase in postoperative risk for hospitalized infection and prosthetic joint infection [<a href="#rid5">5</a>]. Compared with patients who received no glucocorticoids within 90 days of knee or hip replacement surgery, patients who received more than 10 mg of prednisone equivalent daily had a higher predicted risk for hospitalized infection (13.25 versus 6.78 percent) and a higher predicted one-year cumulative incidence of prosthetic joint infection (3.83 versus 2.09 percent). Another population-based study including 381 knee or hip arthroplasties performed in 259 patients with RA found that glucocorticoid doses over prednisone 15 mg (or equivalent) per day were associated with a 20-fold increase in the risk of post-arthroplasty infection [<a href="#rid6">6</a>]. Being overweight and having coronary artery disease were also risk factors for infection.</p><p>There is controversy regarding the role of supraphysiologic (or "stress dose") glucocorticoids in the perioperative setting. There are limited data regarding the optimal approach to managing patients at risk for glucocorticoid-induced adrenal insufficiency, and practices vary among clinicians [<a href="#rid1">1,7,8</a>]. Much of the data come from surgical trials that are not specific to patients with rheumatic diseases. Our approach to glucocorticoid use in the perioperative setting is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a>.)</p><p>Prolonged use of glucocorticoids may cause other complications related to surgery, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired wound healing</p><p class="bulletIndent1"><span class="glyph">●</span>Increased friability of skin and superficial blood vessels</p><p class="bulletIndent1"><span class="glyph">●</span>Hematoma or skin ulceration due to mild pressure</p><p class="bulletIndent1"><span class="glyph">●</span>Increased susceptibility of the skin to tears from adhesive tape</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of fracture, infections, gastrointestinal hemorrhage, or ulcer</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Nonsteroidal antiinflammatory drugs</span><span class="headingEndMark"> — </span>These drugs may need to be stopped prior to surgery to minimize risk of bleeding due to antiplatelet effects and kidney toxicity. Whether to stop them depends on the surgery to be performed and patient factors. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Aspirin'</a> and  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Nonsteroidal antiinflammatory drugs'</a>.) </p><p>The cardiovascular risks associated with the use of nonselective and cyclooxygenase (COX)-2 selective NSAIDs are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Nonbiologic DMARDs</span><span class="headingEndMark"> — </span>Although a reasonable concern exists about the potential of nonbiologic disease-modifying antirheumatic drugs (DMARDs) to increase the risk of infection by affecting the immune response [<a href="#rid9">9,10</a>], stopping DMARDs prior to surgery may result in a flare-up of disease activity, which may adversely affect rehabilitation. In patients taking nonbiologic DMARDs for the treatment of rheumatic diseases, we continue the current dose of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, and/or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> throughout the perioperative period. In clinical practice, the nonbiologic DMARD dose is often missed for one day and up to three days while the patient is hospitalized.</p><p>Several studies of RA patients undergoing elective orthopedic surgery have found that continued use of MTX through the perioperative period is safe [<a href="#rid11">11-13</a>]. As an example, a systematic review including four studies with RA patients undergoing elective orthopedic surgery evaluated the effects of continuing MTX versus stopping MTX in the perioperative period [<a href="#rid13">13</a>]. Continued MTX therapy was safe perioperatively and was associated with a reduced risk of flares. There was no evidence to suggest that stopping MTX preoperatively reduced the incidence of infection or improved wound healing. However, in all of the studies, the mean dose of MTX was less than 15 mg per week. Limited data on the use of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> during the perioperative period are conflicting [<a href="#rid14">14,15</a>]. In one study, there were significantly more wound complications in patients taking leflunomide at the time of elective orthopedic surgery compared with patients on MTX [<a href="#rid15">15</a>]. However, another small study compared patients who continued leflunomide for four weeks prior to arthroplasty versus those who withheld leflunomide and found no difference between the groups [<a href="#rid14">14</a>]. There are also limited data suggesting it is safe to continue <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> in the perioperative period. In a retrospective study of 367 orthopedic surgeries among 204 RA patients, two-thirds of whom were receiving nonbiologic DMARDs including hydroxychloroquine and sulfasalazine, there was no increased infection associated with nonbiologic DMARD use [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Biologic DMARDs</span><span class="headingEndMark"> — </span>In patients taking biologic DMARDs for rheumatic diseases, we withhold the biologic medication and plan the elective surgery at the end of the dosing cycle for that specific medication. These agents should not be restarted until external wound healing is complete, which is typically around two weeks postoperatively.</p><p>As an example, patients taking weekly <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> should aim to schedule the surgery in the second week after the first withheld dose. Patients taking <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> in two-week intervals should plan the surgery in the third week after the first withheld dose. In a similar manner, patients on monthly intravenous <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> should schedule the surgery in the fifth week after the first withheld dose. Patients taking <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> should wait until month 7 after the last dose to schedule the surgery, presumably when B cells have returned to the circulation. However, we do not delay nonelective procedures in patients who have been more recently treated. Additional information regarding the use of these agents for the treatment of rheumatic diseases can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>.)</p><p>There is relatively little evidence available regarding the optimal timing for use of biologic DMARDs in the perioperative period. Our approach is largely based on indirect evidence suggesting that biologic DMARDs are associated with an increased risk of infection in general [<a href="#rid17">17-19</a>] (see  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases"</a>). However, limited data have not demonstrated a clear risk of complications with these agents in the perioperative period.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of postoperative complications</strong> – Many [<a href="#rid20">20-24</a>], but not all [<a href="#rid25">25,26</a>], retrospective studies suggest that the use of biologic DMARDs such as tumor necrosis factor (TNF) inhibitors does not increase the risk of postoperative complications (eg, infection or impaired wound healing). As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Findings from a meta-analysis of cohort studies including data from 7344 patients on biologic DMARDs for systemic rheumatic diseases who were undergoing orthopedic surgery suggested that continuing biologic DMARDs did not appear to be associated with an increased risk of surgical site infections (odds ratio [OR] 1.11, 95% CI 0.82-1.49) and wound complications (OR 2.16, 95% CI 0.48-9.85); however, stopping biologics prior to surgery was associated with a higher risk of disease flares (26 versus 7 percent) [<a href="#rid27">27</a>]. These findings, however, are limited by low-quality evidence from observational studies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subsequent retrospective review that included 1464 patients followed for an average of five years after hip replacement, the need for revision surgery was not significantly different among patients who had received perioperative TNF inhibitors (2.5 percent) versus perioperative conventional synthetic DMARDs (3 percent) [<a href="#rid28">28</a>]. There were also no differences in the risk of perioperative infection or aseptic prosthetic joint loosening.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comparative risk of biologic DMARDs</strong> – Limited data suggest that the comparative infectious risk across biologic DMARDs is similar. Conclusions regarding perioperative safety are largely based on trials in nonoperative patients showing that the infection rate was similar to that in patients receiving placebo [<a href="#rid29">29</a>]. In addition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A propensity score-matched study using insurance claims data from 9911 adults with RA undergoing elective total knee or hip arthroplasty who had a recent infusion of or prescription for <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, or <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> found that risks for hospitalized infection, prosthetic joint infection, and readmission after arthroplasty were similar among the biologic agents [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The infectious risks of <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> are similar to those of TNF inhibitors and other biologic agents, but there are no trials that have examined its safety perioperatively [<a href="#rid17">17,30</a>]. A case series described eight uncomplicated surgeries in seven RA patients on abatacept [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Abatacept'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similarly, there is little evidence regarding the safety of the interleukin 1 (IL-1) receptor inhibitor <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">anakinra</a> in the perioperative period. A retrospective observational study of 100 hospitalized patients receiving IL-1 blockade to treat crystalline arthropathy did not note surgical or infectious complications among the 29 patients treated perioperatively or the 33 who had concomitant bacterial infection [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Anakinra'</a>.)</p><p></p><p class="headingAnchor" id="H1891606057"><span class="h3">Janus kinase inhibitors</span><span class="headingEndMark"> — </span>In patients taking a Janus kinase (JAK) inhibitor (such as <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>), we withhold the JAK inhibitor for at least three days prior to surgery. JAK inhibitors are used in the management of several forms of inflammatory arthritis and other inflammatory disorders. The approach is based on the short half-life of the JAK inhibitors as well as limited data suggesting a rapid increase in disease activity after interrupting therapy, suggesting a reversal of the immunosuppressive effects [<a href="#rid33">33</a>]. However, given the known increased risk of infection associated with tofacitinib [<a href="#rid34">34</a>], withholding JAK inhibitors for a longer period of time (eg, seven days) prior to surgery, particularly in a patient with a history of infections or prior to a prosthetic joint replacement, may be preferable. Information regarding the efficacy and safety of JAK inhibitors is presented separately. (See  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'JAK inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/130611.html" rel="external">"Overview of the Janus kinase inhibitors for rheumatologic and other inflammatory disorders"</a>.)</p><p class="headingAnchor" id="H1012879007"><span class="h3">Other SLE-specific medications</span><span class="headingEndMark"> — </span>There is uncertainty regarding the optimal perioperative medication management in patients with SLE given the lack of data. Medications other than glucocorticoids typically used for SLE patients include <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a>, MTX, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>. Given the clinical spectrum of SLE disease severity and organ involvement, the decision to withhold medications prior to surgery should be made on an individual basis. Thus, for patients with severe SLE and multiorgan involvement in which discontinuation of the medication may result in a disease flare, it is reasonable to continue the medications through the surgical period. This is based on indirect evidence from organ transplant patients that supports continuing anti-rejection therapy during the time of surgery [<a href="#rid35">35,36</a>]. However, if a patient has mild SLE, withholding medications seven days prior to surgery is also reasonable. More data are needed to help guide perioperative medication management in SLE patients.</p><p class="headingAnchor" id="H11"><span class="h1">DISEASE-SPECIFIC ISSUES</span><span class="headingEndMark"> — </span>Certain problems related to particular rheumatic diseases can be anticipated, such as possible atlantoaxial instability in severe, chronic rheumatoid arthritis (RA). Some disease manifestations that can impact perioperative management in patients with Sjögren’s disease, RA, juvenile idiopathic arthritis (JIA), ankylosing spondylitis, psoriatic arthropathy, hemophilic arthropathy, systemic lupus erythematous (SLE), and systemic sclerosis (SSc) are described below. Many of these manifestations will not be present in patients whose disease is mild or well controlled with treatment.</p><p class="headingAnchor" id="H12"><span class="h2">Sjögren's disease</span><span class="headingEndMark"> — </span>Ocular and oral dryness usually accompany Sjögren’s disease. Issues surrounding the management of this condition in the patient undergoing surgery include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">Pilocarpine</a> should not be given in the perioperative period to avoid the risk of bronchospasm, bradycardia, involuntary urination, vomiting, hypotension, and tremor; such manifestations may be confused with postoperative complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lubricating gel and <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> are recommended during and after anesthesia to prevent corneal drying and abrasion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To prevent exacerbating ocular and oral dryness, the use of anticholinergic medications should be minimized.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Rheumatoid arthritis</span><span class="headingEndMark"> — </span>RA is a multisystem disease with wide-ranging implications for perioperative care.</p><p class="bulletIndent1"><span class="glyph">●</span>The systemic and nonarticular manifestations of RA, including atherosclerotic coronary and peripheral vascular disease, heart failure, and pulmonary parenchymal disease, may affect the plans for the management of anesthesia, intraoperative monitoring, and postoperative care. These issues are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Cardiac disease'</a> and  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with RA have an increased risk of atlantoaxial subluxation and neurologic damage, which may be a particular risk during airway management for anesthesia. Risk factors associated with C1-C2 instability include glucocorticoid use, seropositivity, nodular disease, and erosive peripheral joint disease. A soft collar will not stabilize the cervical spine, but it usually reminds the staff to be gentle, particularly when the patient is sedated or unconscious. Lateral cervical radiographs with flexion and extension views of the cervical spine may detect significant subluxation and should be obtained prior to surgery in patients with neck pain or neurologic symptoms or those without symptoms if at high risk [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7518.html" rel="external">"Cervical subluxation in rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cricoarytenoid joint disease may cause difficulty with intubation or airway obstruction after extubation. The physical symptoms of cricoarytenoid arthritis are dyspnea, hoarseness, dysphagia, odynophagia, sense of fullness in the throat, pain with speech, and radiation of pain to the ears. Investigation may be necessary and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">"Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Upper airway obstruction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If multiple joints require replacement, careful timing is necessary to allow optimal rehabilitation. As an example, upper-extremity stabilization may be necessary to enable crutch ambulation prior to lower-extremity surgery. (See  <a class="medical medical_review" href="/z/d/html/7478.html" rel="external">"Surgical management of end-stage rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia also occurs in those with Felty syndrome. Most commonly, such patients do well without any intervention; however, if neutrophil counts are extremely low and result in recurrent infection, granulocyte-colony stimulating factor (G-CSF) can be administered. (See  <a class="medical medical_review" href="/z/d/html/7486.html" rel="external">"Drug therapy in Felty syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RA who undergo total hip or knee replacement are at increased risk of prosthetic joint infection, which is further increased in the setting of revision arthroplasty and a previous prosthetic joint infection [<a href="#rid39">39</a>]. These findings highlight the importance of perioperative prophylactic measures and vigilance during the postoperative period [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/7478.html" rel="external">"Surgical management of end-stage rheumatoid arthritis", section on 'Lower extremity arthroplasty'</a>.) </p><p></p><p class="headingAnchor" id="H14"><span class="h2">Juvenile idiopathic arthritis</span><span class="headingEndMark"> — </span>Since children are skeletally immature, growth disturbances can occur after operation among those with JIA.</p><p class="bulletIndent1"><span class="glyph">●</span>Joint replacement arthroplasty is usually delayed until patients are skeletally mature.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because life expectancy of young patients is greater than that of the prostheses, surgeons may recommend osteotomy as an alternative procedure to joint replacement for those who have a stable joint with a useful functional range of movement, good muscle strength, and some remaining articular cartilage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients with JIA can develop cervical spine involvement and therefore a higher risk of atlantoaxial subluxation and neurologic disease. They may also have micrognathia associated with temporomandibular joint involvement. Both issues can complicate endotracheal intubation but are less common in the modern era due to advances in treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with JIA have higher short-term complication rates after orthopedic surgery when compared with other inflammatory arthritides [<a href="#rid41">41</a>]. This highlights the importance of perioperative optimization and close monitoring for perioperative complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of lung disease associated with systemic-onset JIA may affect plans for the management of anesthesia, intraoperative monitoring, and postoperative care. (See  <a class="medical medical_review" href="/z/d/html/13512.html" rel="external">"Systemic juvenile idiopathic arthritis: Course, prognosis, and complications", section on 'Lung disease'</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Ankylosing spondylitis</span><span class="headingEndMark"> — </span>Problems related to spinal and costovertebral ankylosis may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A substantial risk of operative and perioperative complications if spinal involvement is more than minimal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk of aortic regurgitation and possibly cardiovascular disease. (See  <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">"Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary disease, including restrictive lung disease related to diminished chest wall and spine mobility, and parenchymal disease. (See  <a class="medical medical_review" href="/z/d/html/7785.html" rel="external">"Clinical manifestations of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Pulmonary disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endotracheal intubation may be difficult; flexible scope intubation may be required for severely affected patients. (See  <a class="medical medical_review" href="/z/d/html/89917.html" rel="external">"Flexible scope intubation for anesthesia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positioning for surgery should be planned preoperatively for patients with severe kyphotic deformities, with preparation for the necessary positioning supports and padding. (See  <a class="medical medical_review" href="/z/d/html/94593.html" rel="external">"Patient positioning for surgery and anesthesia in adults", section on 'Trial positioning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive ligamentous calcification and heterotopic ossification may make regional anaesthesia difficult.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative heterotopic ossification may limit total hip arthroplasty success [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Surgery'</a> and  <a class="medical medical_review" href="/z/d/html/7973.html" rel="external">"Complications of total hip arthroplasty", section on 'Heterotopic ossification'</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Psoriatic arthritis</span><span class="headingEndMark"> — </span>Issues in psoriatic arthritis are principally related to skin disease or associated spondylitis:</p><p class="bulletIndent1"><span class="glyph">●</span>There is a risk of flare of psoriatic skin disease at the operative site (Koebner’s phenomenon)</p><p class="bulletIndent1"><span class="glyph">●</span>Stress of surgery may increase the risk of a generalized flare of psoriasis</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Systemic lupus erythematosus</span><span class="headingEndMark"> — </span>Since many patients with SLE have multiorgan involvement, an increased risk of postoperative complications, such as wound infection, kidney function impairment, and pulmonary embolus, may be observed. In addition, hip arthroplasty in patients with SLE is associated with a higher risk of postoperative mortality compared with the general population or patients with RA [<a href="#rid43">43-45</a>].</p><p>Cytopenias are common among patients with SLE but often do not require treatment. Additional information regarding appropriate management of cytopenias can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus", section on 'Cytopenias'</a>.)</p><p class="headingAnchor" id="H3505919622"><span class="h2">Antiphospholipid syndrome</span><span class="headingEndMark"> — </span>Patients with antiphospholipid syndrome (APS) are generally treated with anticoagulation. The treatment of patients with APS and the management of anticoagulation during surgery or an invasive procedure are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Systemic sclerosis (scleroderma)</span><span class="headingEndMark"> — </span>A number of the manifestations of SSc may increase perioperative risk and/or may affect intraoperative and postoperative management.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SSc are at increased risk of pulmonary hypertension, which is associated with a high risk of perioperative complications. Preoperative echocardiography may be indicated for moderate- to high-risk procedures. (See  <a class="medical medical_review" href="/z/d/html/6917.html" rel="external">"Evaluation of perioperative pulmonary risk", section on 'Pulmonary hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Surgical or periprocedural care'</a>.)</p><p></p><p class="bulletIndent1">These patients are also at increased risk of heart failure, conduction block, and arrhythmias, all resulting from fibrosis, and myocardial ischemia, due to non-epicardial coronary artery disease. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Gastrointestinal involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since lung involvement is associated with increased postoperative mortality, preoperative pulmonary function tests and arterial blood gases may be indicated, depending on the complexity of the planned surgery. (See  <a class="medical medical_review" href="/z/d/html/4368.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scleroderma renal disease may cause hypertension or renal crisis. (See  <a class="medical medical_review" href="/z/d/html/7183.html" rel="external">"Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endotracheal intubation may be difficult due to decreased mouth opening and limited neck extension.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SSc are at risk of aspiration with induction of anesthesia, due to esophageal disease and problems with gastric motility. The risk of aspiration must be balanced with the risk of difficult intubation when deciding whether to perform rapid sequence induction and intubation. (See  <a class="medical medical_review" href="/z/d/html/7539.html" rel="external">"Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults", section on 'Gastrointestinal involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be a prolonged response to local anesthetic agents when used for peripheral nerve blocks [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous access may be difficult due to skin thickening.</p><p></p><p class="headingAnchor" id="H720098323"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120132.html" rel="external">"Society guideline links: Preoperative evaluation and perioperative management of patients with rheumatic diseases"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H25851827"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative evaluation</strong> – All patients with rheumatic disease should have a careful preoperative history and physical examination. Preoperative laboratory and imaging studies should be based on patient-specific factors and the planned surgical procedure. (See <a class="local">'Preoperative evaluation'</a> above and <a class="local">'History and physical examination'</a> above and <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk management</strong> – Perioperative care in patients with rheumatic disease requires special attention to the following issues to minimize both risk of disease flare and surgical complications (see <a class="local">'General management principles'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assessing disease activity and optimizing the medication regimen (see <a class="local">'Assessment of disease activity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Recognizing the increased cardiovascular risk associated with rheumatic diseases (see <a class="local">'Cardiac risk assessment'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Addressing states of altered coagulation in patients with antiphospholipid syndrome (APS) (see <a class="local">'Management of thrombophilia in antiphospholipid syndrome'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Minimizing risk of surgical site infections in the setting of immunosuppressive medications (see <a class="local">'Medication management'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative immunosuppressive therapy</strong> – Perioperative management of immunosuppressive therapy is largely based on low-quality evidence and expert opinion. A rheumatologist should be involved in perioperative medication management. Disease severity must be considered in perioperative immunosuppression for patients with some diseases, such as systemic lupus erythematosus. (See <a class="local">'Medication management'</a> above and <a class="local">'Other SLE-specific medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – The major concerns regarding glucocorticoid use in the setting of surgery are risks of (1) surgical site infections and (2) hemodynamic instability (secondary to glucocorticoid-induced adrenal insufficiency). Ideally, the lowest possible dose of glucocorticoids should be used in the perioperative setting in order to minimize these risks. (See <a class="local">'Glucocorticoids'</a> above and  <a class="medical medical_review" href="/z/d/html/146.html" rel="external">"The management of the surgical patient taking glucocorticoids"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsteroidal antiinflammatory drugs</strong> – <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> and other nonsteroidal antiinflammatory drugs (NSAIDs) may need to be stopped prior to surgery to avoid bleeding and kidney damage, depending on the type of NSAID, type of surgery, and other patient factors. (See <a class="local">'Nonsteroidal antiinflammatory drugs'</a> above and  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Aspirin'</a> and  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Nonsteroidal antiinflammatory drugs'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonbiologic disease-modifying antirheumatic drugs</strong> – We continue current doses of nonbiologic disease-modifying antirheumatic drugs (DMARDs) including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, and/or <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> throughout the perioperative period. (See <a class="local">'Nonbiologic DMARDs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Biologic DMARDs</strong> – We withhold biologic DMARDs and plan elective surgery at the end of the dosing cycle for that specific medication. These agents should not be restarted until external wound healing is complete, which is typically around two weeks. (See <a class="local">'Biologic DMARDs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Janus kinase inhibitors</strong> – We withhold Janus kinase (JAK) inhibitors for at least three days prior to surgery. (See <a class="local">'Janus kinase inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-related risks</strong> – Attention should be given to the approaches needed to address the disease-related risks associated with the following disorders:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sjögren's disease (see <a class="local">'Sjögren's disease'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>RA (see <a class="local">'Rheumatoid arthritis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Juvenile idiopathic arthritis (JIA) (see <a class="local">'Juvenile idiopathic arthritis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Ankylosing spondylitis (see <a class="local">'Ankylosing spondylitis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Psoriatic arthritis (see <a class="local">'Psoriatic arthritis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>SLE (see <a class="local">'Systemic lupus erythematosus'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>APS (see <a class="local">'Antiphospholipid syndrome'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic sclerosis (SSc; scleroderma) (see <a class="local">'Systemic sclerosis (scleroderma)'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kelley JT, Conn DL. Perioperative management of the rheumatic disease patient. Bull Rheum Dis 2002; 51.</a></li><li class="breakAll">Figgie MP. Introduction to the surgical treatment of rheumatic diseases. In: Rheumatology, Klippel JH, Dieppe PA (Eds), Mosby, 1994.</li><li><a class="nounderline abstract_t">Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken) 2022; 74:1399.</a></li><li><a class="nounderline abstract_t">Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol 2022; 74:1464.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Winthrop K, et al. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. Ann Intern Med 2019; 170:825.</a></li><li><a class="nounderline abstract_t">Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J 2013; 7:119.</a></li><li><a class="nounderline abstract_t">Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287:236.</a></li><li><a class="nounderline abstract_t">Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66:1560.</a></li><li><a class="nounderline abstract_t">Jain A, Maini R, Nanchahal J. Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data. Ann Rheum Dis 2004; 63:602.</a></li><li><a class="nounderline abstract_t">Salt E, Wiggins AT, Rayens MK, et al. Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis. Semin Arthritis Rheum 2017; 46:423.</a></li><li><a class="nounderline abstract_t">Pieringer H, Stuby U, Biesenbach G. The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008; 27:1217.</a></li><li><a class="nounderline abstract_t">Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60:214.</a></li><li><a class="nounderline abstract_t">Loza E, Martinez-Lopez JA, Carmona L. A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 2009; 27:856.</a></li><li><a class="nounderline abstract_t">Tanaka N, Sakahashi H, Sato E, et al. Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 2003; 9:115.</a></li><li><a class="nounderline abstract_t">Fuerst M, Möhl H, Baumgärtel K, Rüther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 2006; 26:1138.</a></li><li><a class="nounderline abstract_t">Escalante A, Beardmore TD. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 1995; 22:1844.</a></li><li><a class="nounderline abstract_t">Mushtaq S, Goodman SM, Scanzello CR. Perioperative management of biologic agents used in treatment of rheumatoid arthritis. Am J Ther 2011; 18:426.</a></li><li><a class="nounderline abstract_t">Bongartz T. Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions... J Rheumatol 2007; 34:653.</a></li><li><a class="nounderline abstract_t">Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum 2015; 44:627.</a></li><li><a class="nounderline abstract_t">Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004; 25:331.</a></li><li><a class="nounderline abstract_t">Talwalkar SC, Grennan DM, Gray J, et al. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005; 64:650.</a></li><li><a class="nounderline abstract_t">Wendling D, Balblanc JC, Brousse A, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 2005; 64:1378.</a></li><li><a class="nounderline abstract_t">den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34:689.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Hsu JY, et al. Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. Arthritis Care Res (Hoboken) 2017; 69:1845.</a></li><li><a class="nounderline abstract_t">Momohara S, Kawakami K, Iwamoto T, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21:469.</a></li><li><a class="nounderline abstract_t">Clay M, Mazouyes A, Gilson M, et al. Risk of postoperative infections and the discontinuation of TNF inhibitors in patients with rheumatoid arthritis: A meta-analysis. Joint Bone Spine 2016; 83:701.</a></li><li><a class="nounderline abstract_t">van Duren BH, Wignall A, Goodman S, et al. The Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Drugs on the Risk of Postoperative Complications: Surgical Site Infection, Delayed Wound Healing, and Disease Flares Following Orthopaedic Surgical Procedures. J Bone Joint Surg Am 2022; 104:1116.</a></li><li><a class="nounderline abstract_t">Di Martino A, Ursini F, Bordini B, et al. Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study. Semin Arthritis Rheum 2023; 60:152201.</a></li><li><a class="nounderline abstract_t">Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:2838.</a></li><li><a class="nounderline abstract_t">Pham T, Bachelez H, Berthelot JM, et al. Abatacept therapy and safety management. Joint Bone Spine 2012; 79 Suppl 1:3.</a></li><li><a class="nounderline abstract_t">Nishida K, Nasu Y, Hashizume K, et al. Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol 2014; 24:544.</a></li><li><a class="nounderline abstract_t">Liew JW, Gardner GC. Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis. J Rheumatol 2019; 46:1345.</a></li><li><a class="nounderline abstract_t">Kaine J, Tesser J, Takiya L, et al. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol 2020; 39:2127.</a></li><li><a class="nounderline abstract_t">Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015; 17:362.</a></li><li><a class="nounderline abstract_t">Palmisano AC, Kuhn AW, Urquhart AG, Pour AE. Post-operative medical and surgical complications after primary total joint arthroplasty in solid organ transplant recipients: a case series. Int Orthop 2017; 41:13.</a></li><li><a class="nounderline abstract_t">Klement MR, Penrose CT, Bala A, et al. How Do Previous Solid Organ Transplant Recipients Fare After Primary Total Knee Arthroplasty? J Arthroplasty 2016; 31:609.</a></li><li><a class="nounderline abstract_t">Neva MH, Häkkinen A, Mäkinen H, et al. High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis 2006; 65:884.</a></li><li><a class="nounderline abstract_t">Lopez-Olivo MA, Andrabi TR, Palla SL, Suarez-Almazor ME. Cervical spine radiographs in patients with rheumatoid arthritis undergoing anesthesia. J Clin Rheumatol 2012; 18:61.</a></li><li><a class="nounderline abstract_t">Kurdi AJ, Voss BA, Tzeng TH, et al. Rheumatoid Arthritis vs Osteoarthritis: Comparison of Demographics and Trends of Joint Replacement Data from the Nationwide Inpatient Sample. Am J Orthop (Belle Mead NJ) 2018; 47.</a></li><li><a class="nounderline abstract_t">Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59:1713.</a></li><li><a class="nounderline abstract_t">Schnaser EA, Browne JA, Padgett DE, et al. Perioperative Complications in Patients With Inflammatory Arthropathy Undergoing Total Hip Arthroplasty. J Arthroplasty 2016; 31:2286.</a></li><li><a class="nounderline abstract_t">Sundaram NA, Murphy JC. Heterotopic bone formation following total hip arthroplasty in ankylosing spondylitis. Clin Orthop Relat Res 1986; :223.</a></li><li><a class="nounderline abstract_t">Domsic RT, Lingala B, Krishnan E. Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol 2010; 37:1467.</a></li><li><a class="nounderline abstract_t">Roberts JE, Mandl LA, Su EP, et al. Patients with Systemic Lupus Erythematosus Have Increased Risk of Short-term Adverse Events after Total Hip Arthroplasty. J Rheumatol 2016; 43:1498.</a></li><li><a class="nounderline abstract_t">Merayo-Chalico J, Gónzalez-Contreras M, Ortíz-Hernández R, et al. Total Hip Arthroplasty Outcomes: An 18-Year Experience in a Single Center: Is Systemic Lupus Erythematosus a Potential Risk Factor for Adverse Outcomes? J Arthroplasty 2017; 32:3462.</a></li><li><a class="nounderline abstract_t">Dempsey ZS, Rowell S, McRobert R. The role of regional and neuroaxial anesthesia in patients with systemic sclerosis. Local Reg Anesth 2011; 4:47.</a></li></ol></div><div id="topicVersionRevision">Topic 1826 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Perioperative management of the rheumatic disease patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Perioperative management of the rheumatic disease patient</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35718887" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35722708" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31108503" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24454587" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk factors for infection following total joint arthroplasty in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11779267" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Corticosteroid supplementation for adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660219" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082498" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27692433" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18414965" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171680" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917174" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17041441" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16736164" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8991980" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20216205" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Perioperative management of biologic agents used in treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407223" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions...</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25747348" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rheumatoid arthritis: Perioperative management of biologics and DMARDs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15134615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15769927" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100348" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17117492" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28129484" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21318306" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118016" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of postoperative infections and the discontinuation of TNF inhibitors in patients with rheumatoid arthritis: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35175994" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Drugs on the Risk of Postoperative Complications: Surgical Site Infection, Delayed Wound Healing, and Disease Flares Following Orthopaedic Surgical Procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37028127" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12428223" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22541956" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Abatacept therapy and safety management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24506697" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30647192" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32048083" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26669566" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27497936" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Post-operative medical and surgical complications after primary total joint arthroplasty in solid organ transplant recipients: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26639984" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : How Do Previous Solid Organ Transplant Recipients Fare After Primary Total Knee Arthroplasty?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16269427" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22334269" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cervical spine radiographs in patients with rheumatoid arthritis undergoing anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30075040" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rheumatoid Arthritis vs Osteoarthritis: Comparison of Demographics and Trends of Joint Replacement Data from the Nationwide Inpatient Sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035425" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133160" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Perioperative Complications in Patients With Inflammatory Arthropathy Undergoing Total Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3087671" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Heterotopic bone formation following total hip arthroplasty in ankylosing spondylitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472923" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307529" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patients with Systemic Lupus Erythematosus Have Increased Risk of Short-term Adverse Events after Total Hip Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709759" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Total Hip Arthroplasty Outcomes: An 18-Year Experience in a Single Center: Is Systemic Lupus Erythematosus a Potential Risk Factor for Adverse Outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22915893" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The role of regional and neuroaxial anesthesia in patients with systemic sclerosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
